H-1B sponsorship profile: Novartis Pharmaceuticals Corporation. Across U.S. Department of Labor LCA disclosures, Novartis Pharmaceuticals Corporation filed 335 Labor Condition Applications covering 335 H-1B worker positions between fiscal year 2023 and fiscal year 2026. The employer’s DOL certification rate sits at 99.1% (332 certified of 335 filed), a useful proxy for how cleanly their prevailing-wage attestations pass the Labor Department’s preliminary review before USCIS adjudication.

Compensation spread. Offered wages on Novartis Pharmaceuticals Corporation’s H-1B petitions range from $62,629 at the low end to $241,592 at the high end, with a petition-weighted average of $139,527. That range reflects the mix of occupations the company sponsors, led by Principal Biostatistician (40 petitions at $123,280 avg), followed by Senior Principal Biostatistician and Principal Pharmacometrician. H-1B salaries reported on LCAs must meet or exceed the DOL prevailing wage for the role and worksite, so the spread also tracks wage-level geography and seniority.

Geographic footprint. Novartis Pharmaceuticals Corporation is headquartered in EAST HANOVER, NJ under NAICS code 541713, and places H-1B workers across 3 states, most heavily in NJ, MA, NC. Combined, these signals give a granular view of how one employer uses the H-1B program, volume, approval cleanliness, wage posture, and where the jobs actually sit on the map.

Where Novartis Pharmaceuticals Corporation ranks. By H-1B petition volume, Novartis Pharmaceuticals Corporation is #581 of 119,880 employers nationally and #52 of 5,818 employers headquartered in NJ. Both ranks are computed live from the same underlying petition counts, not a separate estimate.